What's in Taiwan Liposome Company's pipeline?

Taiwan Liposome Company has 12 drugs in our index: 3 marketed, 0 filed, 2 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with Taiwan Liposome Company's portfolio?

Top competitors by shared drug class: Bharat Serums and Vaccines Limited, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., Dr. Falk Pharma GmbH, Drugs for Neglected Diseases.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/taiwan-liposome-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Taiwan Liposome Company — Portfolio Competitive Intelligence Brief

Taiwan Liposome Company pipeline: 3 marketed, 0 filed, 2 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 2 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
AmBisome	AmBisome	marketed
DSP	DSP	marketed	Liposomal anthracycline chemotherapy	Topoisomerase II	Oncology
Liposomal Amphotericin B	Liposomal Amphotericin B	marketed	Polyene antifungal	Ergosterol	Infectious Disease
TLC590	TLC590	phase 3
TLC599	TLC599	phase 3	chemotherapeutic agent		Oncology

Therapeutic area mix

Oncology · 2
Other · 2
Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bharat Serums and Vaccines Limited · 1 shared drug class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 shared drug class
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 1 shared drug class
Dr. Falk Pharma GmbH · 1 shared drug class
Drugs for Neglected Diseases · 1 shared drug class
Federal University of Health Science of Porto Alegre · 1 shared drug class
Fundacion Nacional de Dermatologia · 1 shared drug class
Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Taiwan Liposome Company:

Cite this brief

Drug Landscape (2026). Taiwan Liposome Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/taiwan-liposome-company. Accessed 2026-05-16.